Overview

Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to provide evidence that Compound Sodium Alginate Double Action Chewable Tablets are effective in managing the symptoms of heartburn, acid regurgitation and dyspepsia in patients with Gastroesophageal Reflux Disease (GERD).
Phase:
Phase 3
Details
Lead Sponsor:
Reckitt Benckiser Healthcare (UK) Limited
Treatments:
Alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination
Alginic acid